Accolade acquired by Transcarent
Context
Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group. The strategic rationale is centered on the creation of a unified, AI‑driven “One Place for Health and Care” platform. Transcarent’s WayFinding experience, generative AI‑powered navigation, and complex‑care pathways in Cancer Care, Surgery Care, and Weight Health are combined with Accolade’s strengths in health advocacy, expert medical opinions (EMO), and virtual primary care. This integration allows members to access benefits navigation, clinical guidance, and end‑to‑end care delivery through a single interface, with the explicit goal of improving utilization patterns, lowering total care costs, and enhancing member experience for employers and payers. The combined organization now serves over 20 million members and more than 1,700 employer and health‑plan clients, creating a large‑scale, digitally‑native health services platform with significant optionality for cross‑selling, technology integration, and further ecosystem expansion.
Accolade, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, standing directly in line with the average observed in the Healthcare & Pharma sector (14.5x in 2025).
-> Deep-dive in Healthcare & Pharma market trends
Target
Accolade is a US‑based digital health and personalized healthcare company headquartered in Seattle, Washington, offering health advocacy, expert medical opinion, and virtual primary care services. The company provides an integrated platform that helps members navigate benefits, connect with clinicians, and access high‑quality care, with a strong focus on employer‑ and health‑plan‑sponsored populations. Accolade’s offering combines virtual care delivery, care navigation, and a personal advocate model, often integrated with employers’ benefit ecosystems. The company positions itself as a “personalized healthcare” solution, leveraging predictive analytics, data‑driven engagement, and a large member base to proactively guide care pathways and reduce fragmentation. Its platform supports population health needs from early‑stage intervention through more complex care episodes, with high consumer satisfaction ratings typically above 90%. Accolade’s model benefits from ongoing employer and health‑plan demand for value‑based, guidance‑oriented digital health services.
Ent. Value
$500M–1.5bn
Equity Value
[members only]
Multiples
EV / Revenue
below 1.5x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (USD)
Similar deals in Healthcare Services
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2025 | EVOLEM | APPERTON | FRANCE | Sterilization & Hygiene |
| 05/2025 | FIVE ARROWS | HUBLO | FRANCE | Health Tech |
| 04/2025 | KERSIA | NEOGEN (ANIMAL BIOSECURITY DIVISION) | UNITED STATES | Sterilization & Hygiene |
| 10/2024 | FULLSCRIPT | RUPA HEALTH | UNITED STATES | Health Tech |
| 07/2024 | ARDIAN | MASCO GROUP | ITALY | Healthcare Services |
| 06/2024 | PERMIRA | PHARMACORD | UNITED STATES | Health Tech |
| 05/2024 | 21 INVEST / OAKLEY CAPITAL INVESTMENTS | PRODUCT LIFE | FRANCE | Healthcare Services |
| 10/2023 | MOTION EQUITY PARTNERS | BANOOK | FRANCE | CRO / Clinical Trials |
| 09/2023 | PERMIRA | ERGOMED | UNITED KINGDOM | CRO / Clinical Trials |
| 09/2023 | CERBA HEALTHCARE | CIRION BIOPHARMA RESEARCH | CANADA | CRO / Clinical Trials |
REFERENCES
Valuation range: EV $500M–1.5bn
Revenue range: $450–900M
EBITDA range: $25–50M
EV/Revenue range: below 1.5x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Accolade by Transcarent are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: accolade
Acquirer: transcarent
FAQ
What transaction does this page cover?
How was the acquisition of Accolade by Transcarent valued, and what multiples were paid?
What were Accolade’s revenue and EBITDA at the time of the deal?
How does the valuation of Accolade compare to benchmarks in the Healthcare & Pharma sector?
What sources support the information on this transaction?
What is mynth?